Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure: The COGiTATE phase II study protocol

Erta Beqiri, Peter Smielewski, Chiara Robba, Marek Czosnyka, Manuel Teixeira Cabeleira, Jeanette Tas, Joseph Donnelly, Joanne G. Outtrim, Peter Hutchinson, David Menon, Geert Meyfroidt, Bart Depreitere, Marcel J. Aries, Ari Ercole

Research output: Contribution to journalArticle

Abstract

Introduction Individualising therapy is an important challenge for intensive care of patients with severe traumatic brain injury (TBI). Targeting a cerebral perfusion pressure (CPP) tailored to optimise cerebrovascular autoregulation has been suggested as an attractive strategy on the basis of a large body of retrospective observational data. The objective of this study is to prospectively assess the feasibility and safety of such a strategy compared with fixed thresholds which is the current standard of care from international consensus guidelines. Methods and analysis CPPOpt Guided Therapy: Assessment of Target Effectiveness (COGiTATE) is a prospective, multicentre, non-blinded randomised, controlled trial coordinated from Maastricht University Medical Center, Maastricht (The Netherlands). The other original participating centres are Cambridge University NHS Foundation Trust, Cambridge (UK), and University Hospitals Leuven, Leuven (Belgium). Adult severe TBI patients requiring intracranial pressure monitoring are randomised within the first 24 hours of admission in neurocritical care unit. For the control arm, the CPP target is the Brain Trauma Foundation guidelines target (60-70 mm Hg); for the intervention group an automated CPP target is provided as the CPP at which the patient's cerebrovascular reactivity is best preserved (CPPopt). For a maximum of 5 days, attending clinicians review the CPP target 4-hourly. The main hypothesis of COGiTATE are: (1) in the intervention group the percentage of the monitored time with measured CPP within a range of 5 mm Hg above or below CPPopt will reach 36%; (2) the difference in between groups in daily therapy intensity level score will be lower or equal to 3. Ethics and dissemination Ethical approval has been obtained for each participating centre. The results will be presented at international scientific conferences and in peer-reviewed journals. Trial registration number NCT02982122

Original languageEnglish
Article numbere030727
JournalBMJ Open
Volume9
Issue number9
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Cerebrovascular Circulation
Therapeutics
Guidelines
Belgium
Intracranial Pressure
Critical Care
Standard of Care
Ethics
Netherlands
Traumatic Brain Injury
Homeostasis
Safety

Keywords

  • autoregulation
  • COGiTATE
  • individualised TBI management
  • intensive care
  • Optimal CPP
  • precision medicine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure : The COGiTATE phase II study protocol. / Beqiri, Erta; Smielewski, Peter; Robba, Chiara; Czosnyka, Marek; Cabeleira, Manuel Teixeira; Tas, Jeanette; Donnelly, Joseph; Outtrim, Joanne G.; Hutchinson, Peter; Menon, David; Meyfroidt, Geert; Depreitere, Bart; Aries, Marcel J.; Ercole, Ari.

In: BMJ Open, Vol. 9, No. 9, e030727, 01.01.2019.

Research output: Contribution to journalArticle

Beqiri, E, Smielewski, P, Robba, C, Czosnyka, M, Cabeleira, MT, Tas, J, Donnelly, J, Outtrim, JG, Hutchinson, P, Menon, D, Meyfroidt, G, Depreitere, B, Aries, MJ & Ercole, A 2019, 'Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure: The COGiTATE phase II study protocol', BMJ Open, vol. 9, no. 9, e030727. https://doi.org/10.1136/bmjopen-2019-030727
Beqiri, Erta ; Smielewski, Peter ; Robba, Chiara ; Czosnyka, Marek ; Cabeleira, Manuel Teixeira ; Tas, Jeanette ; Donnelly, Joseph ; Outtrim, Joanne G. ; Hutchinson, Peter ; Menon, David ; Meyfroidt, Geert ; Depreitere, Bart ; Aries, Marcel J. ; Ercole, Ari. / Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure : The COGiTATE phase II study protocol. In: BMJ Open. 2019 ; Vol. 9, No. 9.
@article{60e40df83e76465d9970657a531f8846,
title = "Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure: The COGiTATE phase II study protocol",
abstract = "Introduction Individualising therapy is an important challenge for intensive care of patients with severe traumatic brain injury (TBI). Targeting a cerebral perfusion pressure (CPP) tailored to optimise cerebrovascular autoregulation has been suggested as an attractive strategy on the basis of a large body of retrospective observational data. The objective of this study is to prospectively assess the feasibility and safety of such a strategy compared with fixed thresholds which is the current standard of care from international consensus guidelines. Methods and analysis CPPOpt Guided Therapy: Assessment of Target Effectiveness (COGiTATE) is a prospective, multicentre, non-blinded randomised, controlled trial coordinated from Maastricht University Medical Center, Maastricht (The Netherlands). The other original participating centres are Cambridge University NHS Foundation Trust, Cambridge (UK), and University Hospitals Leuven, Leuven (Belgium). Adult severe TBI patients requiring intracranial pressure monitoring are randomised within the first 24 hours of admission in neurocritical care unit. For the control arm, the CPP target is the Brain Trauma Foundation guidelines target (60-70 mm Hg); for the intervention group an automated CPP target is provided as the CPP at which the patient's cerebrovascular reactivity is best preserved (CPPopt). For a maximum of 5 days, attending clinicians review the CPP target 4-hourly. The main hypothesis of COGiTATE are: (1) in the intervention group the percentage of the monitored time with measured CPP within a range of 5 mm Hg above or below CPPopt will reach 36{\%}; (2) the difference in between groups in daily therapy intensity level score will be lower or equal to 3. Ethics and dissemination Ethical approval has been obtained for each participating centre. The results will be presented at international scientific conferences and in peer-reviewed journals. Trial registration number NCT02982122",
keywords = "autoregulation, COGiTATE, individualised TBI management, intensive care, Optimal CPP, precision medicine",
author = "Erta Beqiri and Peter Smielewski and Chiara Robba and Marek Czosnyka and Cabeleira, {Manuel Teixeira} and Jeanette Tas and Joseph Donnelly and Outtrim, {Joanne G.} and Peter Hutchinson and David Menon and Geert Meyfroidt and Bart Depreitere and Aries, {Marcel J.} and Ari Ercole",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/bmjopen-2019-030727",
language = "English",
volume = "9",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure

T2 - The COGiTATE phase II study protocol

AU - Beqiri, Erta

AU - Smielewski, Peter

AU - Robba, Chiara

AU - Czosnyka, Marek

AU - Cabeleira, Manuel Teixeira

AU - Tas, Jeanette

AU - Donnelly, Joseph

AU - Outtrim, Joanne G.

AU - Hutchinson, Peter

AU - Menon, David

AU - Meyfroidt, Geert

AU - Depreitere, Bart

AU - Aries, Marcel J.

AU - Ercole, Ari

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction Individualising therapy is an important challenge for intensive care of patients with severe traumatic brain injury (TBI). Targeting a cerebral perfusion pressure (CPP) tailored to optimise cerebrovascular autoregulation has been suggested as an attractive strategy on the basis of a large body of retrospective observational data. The objective of this study is to prospectively assess the feasibility and safety of such a strategy compared with fixed thresholds which is the current standard of care from international consensus guidelines. Methods and analysis CPPOpt Guided Therapy: Assessment of Target Effectiveness (COGiTATE) is a prospective, multicentre, non-blinded randomised, controlled trial coordinated from Maastricht University Medical Center, Maastricht (The Netherlands). The other original participating centres are Cambridge University NHS Foundation Trust, Cambridge (UK), and University Hospitals Leuven, Leuven (Belgium). Adult severe TBI patients requiring intracranial pressure monitoring are randomised within the first 24 hours of admission in neurocritical care unit. For the control arm, the CPP target is the Brain Trauma Foundation guidelines target (60-70 mm Hg); for the intervention group an automated CPP target is provided as the CPP at which the patient's cerebrovascular reactivity is best preserved (CPPopt). For a maximum of 5 days, attending clinicians review the CPP target 4-hourly. The main hypothesis of COGiTATE are: (1) in the intervention group the percentage of the monitored time with measured CPP within a range of 5 mm Hg above or below CPPopt will reach 36%; (2) the difference in between groups in daily therapy intensity level score will be lower or equal to 3. Ethics and dissemination Ethical approval has been obtained for each participating centre. The results will be presented at international scientific conferences and in peer-reviewed journals. Trial registration number NCT02982122

AB - Introduction Individualising therapy is an important challenge for intensive care of patients with severe traumatic brain injury (TBI). Targeting a cerebral perfusion pressure (CPP) tailored to optimise cerebrovascular autoregulation has been suggested as an attractive strategy on the basis of a large body of retrospective observational data. The objective of this study is to prospectively assess the feasibility and safety of such a strategy compared with fixed thresholds which is the current standard of care from international consensus guidelines. Methods and analysis CPPOpt Guided Therapy: Assessment of Target Effectiveness (COGiTATE) is a prospective, multicentre, non-blinded randomised, controlled trial coordinated from Maastricht University Medical Center, Maastricht (The Netherlands). The other original participating centres are Cambridge University NHS Foundation Trust, Cambridge (UK), and University Hospitals Leuven, Leuven (Belgium). Adult severe TBI patients requiring intracranial pressure monitoring are randomised within the first 24 hours of admission in neurocritical care unit. For the control arm, the CPP target is the Brain Trauma Foundation guidelines target (60-70 mm Hg); for the intervention group an automated CPP target is provided as the CPP at which the patient's cerebrovascular reactivity is best preserved (CPPopt). For a maximum of 5 days, attending clinicians review the CPP target 4-hourly. The main hypothesis of COGiTATE are: (1) in the intervention group the percentage of the monitored time with measured CPP within a range of 5 mm Hg above or below CPPopt will reach 36%; (2) the difference in between groups in daily therapy intensity level score will be lower or equal to 3. Ethics and dissemination Ethical approval has been obtained for each participating centre. The results will be presented at international scientific conferences and in peer-reviewed journals. Trial registration number NCT02982122

KW - autoregulation

KW - COGiTATE

KW - individualised TBI management

KW - intensive care

KW - Optimal CPP

KW - precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85072586381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072586381&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2019-030727

DO - 10.1136/bmjopen-2019-030727

M3 - Article

C2 - 31542757

AN - SCOPUS:85072586381

VL - 9

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 9

M1 - e030727

ER -